A Global Leader in
Molecular Glue Degrader-Based Drug Discovery
GluBio Therapeutics, Inc. is a biotech company dedicated to the discovery and development of innovative molecular glue degraders (MGDs). Founded in March 2021, GluBio operates R&D centers in Zhangjiang Science City, Shanghai, and San Diego, California.
As a global leader in molecular glue degrader biotechnology, GluBio is powered by an experienced international leadership team in molecular glue R&D. The company has built a highly efficient, proprietary molecular glue discovery platform and is advancing molecular glue therapeutics across multiple disease areas, including oncology, autoimmune disorders, and genetic diseases, to address unmet clinical needs.
Pipeline
Focused on discovering and developing ‘First-in-class’ and ‘Best-in-class’ molecular glue–based protein degradation therapies.
CK1αLatest News
-
August 31, 2026GluBio’s WIZ Molecular Glue Degrader GLB-005 Included in CDE Patient-Centered Action for Rare Diseases Encouragement PlanLearn More
-
April 28, 2026GluBio’s Novel Oral Molecular Glue Degrader GLB-002 Combined with Rituximab Secures Phase II Clinical Trial ApprovalLearn More
-
February 11, 2026Sanofi Makes $30 Million Strategic Investment in GluBio Therapeutics to Advance Molecular Glue Degraders for Sickle Cell DiseaseLearn More